LP
NAGE

LMR Partners’s Niagen Bioscience NAGE Stock Holding History

LMR Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,717
Closed -$21K – 1306
2022
Q3 		$21K Hold
16,717
– – ﹤0.01% 1162
2022
Q2 		$28K Buy
+16,717
New +$32.7K ﹤0.01% 1213
2017
Q3 		– Sell
-90,841
Closed -$347K – 574
2017
Q2 		$347K Buy
+90,841
New +$288K 0.02% 453

Other funds holding NAGE

TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LMR Partners's NAGE Position: Q4 2022 in Review

LMR Partners sold out of Niagen Bioscience (NAGE) in Q4 2022, closing a stake of 16,717 shares — an estimated $21K sold.

LMR Partners first reported a position in NAGE in Q2 2017 and held it in 3 quarters. The position peaked at $347K in Q2 2017. 59 funds tracked by Wall St. Rank hold NAGE as of Q4 2022.

  • LMR Partners reported no remaining Niagen Bioscience position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 16,717 Niagen Bioscience shares in Q4 2022, an estimated $21K.
  • LMR Partners first reported a position in Niagen Bioscience in Q2 2017 and held it in 3 quarters.
  • LMR Partners's Niagen Bioscience position peaked at $347K in Q2 2017.
  • 59 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.